吉西他滨联合顺铂化疗在晚期非小细胞肺癌患者中的应用及对CYFRA21-1、VEGF的影响分析  

Application of gemcitabine combined with cisplatin chemotherapy in patients with advanced non-small cell lung cancer and its influence on CYFRA21-1 and VEGF

作　　者：苏秋波 SU Qiu-bo(Department of Oncology,Caoxian County People's Hospital,Heze 274400,China)

机构地区：[1]曹县人民医院肿瘤科,274400

出　　处：《中国现代药物应用》2023年第13期109-111,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探讨吉西他滨联合顺铂化疗在晚期非小细胞肺癌患者中的应用效果及对血管内皮生长因子(VEGF)与细胞角蛋白19片段抗原21-1(CYFRA21-1)的影响。方法94例晚期非小细胞肺癌患者,以随机数字表法分为研究组与对照组,各47例。对照组行紫杉醇联合顺铂化疗方案治疗,研究组行吉西他滨联合顺铂化疗方案治疗。比较两组疗效,治疗前后的CYFRA21-1、VEGF水平,不良反应发生情况。结果研究组治疗总有效率59.57%高于对照组的38.30%,差异有统计学意义(P<0.05)。治疗后,研究组CYFRA21-1(3.65±0.52)μg/L、VEGF(120.05±13.52)ng/ml低于对照组的(4.53±0.47)μg/L、(155.65±14.03)ng/ml,差异有统计学意义(P<0.05)。研究组不良反应发生率42.55%与对照组的57.45%比较,差异无统计学意义(P>0.05)。结论晚期非小细胞肺癌患者接受吉西他滨联合顺铂化疗可以取得满意的效果,且有效下调了CYFRA21-1及VEGF水平,适于临床推广。Objective To discuss the application effect of gemcitabine combined with cisplatin chemotherapy in patients with advanced non-small cell lung cancer and its influence on cytokeratin 19 fragment antigen 21-1(CYFRA21-1)and vascular endothelial growth factor(VEGF).Methods A total of 94 patients with advanced non-small cell lung cancer were randomly divided into research group and control group,with 47 cases in each group.The control group was treated with paclitaxel combined with cisplatin chemotherapy regimen,and the research group was treated with gemcitabine combined with cisplatin chemotherapy regimen.The efficacy,levels of CYFRA21-1 and VEGF before and after treatment,and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the research group was 59.57%,which was higher than that of 38.30%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CYFRA21-1 and VEGF were(3.65±0.52)μg/L and(120.05±13.52)ng/ml in the research group,which were lower than those of(4.53±0.47)μg/L and(155.65±14.03)ng/ml in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions was 42.55%in the research group,which was not statistically significant compared with 57.45%in the control group(P>0.05).Conclusion Patients with advanced non-small cell lung cancer receiving gemcitabine combined with cisplatin chemotherapy can achieve satisfactory results and effectively downregulate CYFRA21-1 and VEGF levels,which is suitable for clinical promotion.

关 键 词：吉西他滨 顺铂 化疗 晚期 非小细胞肺癌 血管内皮生长因子 细胞角蛋白19片段抗原21-1 

分 类 号：R734.2[医药卫生—肿瘤]